Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Alkermes plc, una empresa biofarmacéutica, se dedica a la investigación, el desarrollo y la comercialización de productos farmacéuticos para abordar las necesidades médicas no satisfechas de los pacientes en áreas terapéuticas en los Estados Unidos, Irlanda e internacionalmente. La empresa cuenta con una cartera de productos comerciales patentados para el tratamiento de la dependencia de opioides, la dependencia del alcohol, la esquizofrenia y el trastorno bipolar I, y una cartera de productos clínicos y preclínicos candidatos en desarrollo para trastornos neurológicos.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $1.7B | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B | $1.0B | $1.2B | $1.1B | $903M | $746M | $628M | $619M | $596M | $576M | $576M | $390M | $187M | $178M | $327M | $241M |
| Beneficio bruto | $1.4B | $1.3B | $1.3B | $1.4B | $894M | $976M | $860M | $991M | $918M | $749M | $614M | $489M | $443M | — | $265M | $405M | $262M | $134M | $129M | $283M | $200M |
| % de margen bruto | 84.6% | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% | 84.6% | 83.9% | 82.9% | 82.3% | 77.9% | 71.6% | 69.0% | 46.1% | 70.4% | 67.3% | 72.0% | 72.3% | 86.7% | 83.1% |
| Ingresos operativos (EBIT) | $117M | $254M | $421M | $414M | ($6M) | $98M | ($112M) | ($175M) | ($99M) | ($148M) | ($209M) | ($224M) | ($87M) | $16M | $82M | $82M | ($88M) | ($46M) | ($43M) | $135M | ($3M) |
| % de margen operativo | 7.0% | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% | -15.0% | -9.1% | -16.4% | -28.0% | -35.7% | -14.1% | 3.6% | 14.2% | 14.2% | -22.6% | -24.4% | -24.1% | 41.3% | -1.2% |
| Ingresos netos | $66M | $242M | $367M | $356M | ($158M) | ($48M) | ($111M) | ($197M) | ($139M) | ($158M) | ($208M) | ($227M) | ($30M) | $18M | $25M | $25M | ($114M) | ($46M) | ($40M) | $131M | $167M |
| % de margen neto | 4.0% | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% | -36.1% | -4.9% | 4.1% | 4.3% | 4.3% | -29.1% | -24.4% | -22.2% | 39.9% | 69.4% |
| EBITDA | $218M | $331M | $495M | $519M | $60M | $178M | ($6M) | ($103M) | ($8M) | ($33M) | ($105M) | ($125M) | $97M | $66M | $115M | $158M | ($38M) | ($35M) | ($14M) | $155M | $16M |
| Beneficio por acción (EPS) | $0.39 | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.30 | $-0.70 | $-1.25 | $-0.90 | $-1.03 | $-1.38 | $-1.52 | $-0.21 | $0.12 | $0.18 | $0.18 | $-1.19 | $-0.48 | $-0.42 | $1.36 | $1.62 |
| Acciones en circulación (M) | 167M | 169M | 169M | 170M | 164M | 161M | 159M | 157M | 155M | 153M | 151M | 149M | 145M | 145M | 137M | 137M | 96M | 96M | 95M | 96M | 103M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de ALKS. /companies/us/ALKS
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms